Literature DB >> 34508958

Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.

Jessica J Wyse1, Benjamin J Morasco2, Jacob Dougherty3, Beau Edwards4, Devan Kansagara5, Adam J Gordon6, P Todd Korthuis7, Anaïs Tuepker8, Stephan Lindner9, Katherine Mackey10, Beth Williams11, Anders Herreid-O'Neill12, Robin Paynter13, Travis I Lovejoy14.   

Abstract

BACKGROUND: A growing body of research has examined adjunctive interventions supportive of engagement and retention in treatment among patients receiving buprenorphine for opioid use disorder (OUD). We conducted a systematic review of the literature addressing the effect on key outcomes of adjunctive interventions provided alongside standard medical management of buprenorphine in outpatient settings.
METHODS: We included prospective studies examining adults receiving buprenorphine paired with an adjunctive intervention for the treatment of OUD in an outpatient setting. Data sources included Medline, Cochrane Central Register of Controlled Trials, CINAHL and PsycINFO from inception through January 2020. Two raters independently reviewed full-text articles, abstracted data and appraised risk of bias. Outcomes examined included abstinence, retention in treatment and non-addiction-related health outcomes.
RESULTS: The final review includes 20 manuscripts, 11 randomized control trials (RCTs), three secondary analyses of RCTs and six observational studies. Most studies examined psychosocial interventions (n = 14). Few examined complementary therapies (e.g., yoga; n = 2) or technological interventions (e.g., electronic pill dispensation; n = 3); one study examined an intervention addressing structural barriers to care (patient navigators; n = 1). Low risk of bias RCTs found no evidence that adding psychosocial interventions to buprenorphine treatment improves substance use outcomes.
CONCLUSIONS: Research is needed to identify adjunctive interventions with potential to support medication adherence and addiction-related outcomes for patients engaged in buprenorphine treatment. Data from clinical trials suggest that lack of ready access to psychosocial treatments should not discourage clinicians from prescribing buprenorphine.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Buprenorphine; Opioid-related disorders; Outpatients; Psychosocial treatment

Mesh:

Substances:

Year:  2021        PMID: 34508958      PMCID: PMC9063385          DOI: 10.1016/j.drugalcdep.2021.108923

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.852


  55 in total

1.  Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.

Authors:  Ryoko Susukida; Rosa M Crum; Cyrus Ebnesajjad; Elizabeth A Stuart; Ramin Mojtabai
Journal:  Addiction       Date:  2017-03-16       Impact factor: 6.526

2.  The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up.

Authors:  Charles Ruetsch; Joseph Tkacz; Tracy L McPherson; John Cacciola
Journal:  Addict Behav       Date:  2012-01-25       Impact factor: 3.913

3.  A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.

Authors:  Michael D Stein; Debra S Herman; Ethan Moitra; Jacki Hecht; Rosalie Lopez; Bradley J Anderson; Richard A Brown
Journal:  Drug Alcohol Depend       Date:  2014-11-26       Impact factor: 4.492

Review 4.  The Next Stage of Buprenorphine Care for Opioid Use Disorder.

Authors:  Stephen A Martin; Lisa M Chiodo; Jordon D Bosse; Amanda Wilson
Journal:  Ann Intern Med       Date:  2018-10-23       Impact factor: 25.391

5.  Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.

Authors:  Kelly Alanis-Hirsch; Raina Croff; James H Ford; Kim Johnson; Mady Chalk; Laura Schmidt; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2015-11-06

Review 6.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

7.  A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.

Authors:  David A Fiellin; Declan T Barry; Lynn E Sullivan; Christopher J Cutter; Brent A Moore; Patrick G O'Connor; Richard S Schottenfeld
Journal:  Am J Med       Date:  2013-01       Impact factor: 4.965

8.  Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Authors:  Roger D Weiss; Margaret L Griffin; Jennifer Sharpe Potter; Dorian R Dodd; Jessica A Dreifuss; Hilary S Connery; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2014-04-24       Impact factor: 4.492

9.  Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone.

Authors:  Laura Lander; Kathleen Chiasson-Downs; Michael Andrew; Gerald Rader; Sheena Dohar; Kimberly Waibogha
Journal:  J Addict Res Ther       Date:  2017-12-10

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more
  2 in total

1.  Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.

Authors:  Hillary Samples; Arthur Robin Williams; Stephen Crystal; Mark Olfson
Journal:  J Subst Abuse Treat       Date:  2022-03-18

2.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.